2024. Ten-Year Response to Crizotinib in ALK-positive Inflammatory Myofibroblastic Tumors: Case Reports. Voprosy onkologii. 70, 2 (May 2024), 384–389. DOI:https://doi.org/10.37469/0507-3758-2024-70-2-384-389.